huntingtin interacting protein KGenealiases: C15orf63 · HSPC136
Q-omics provides the consensus-scored HYPK profile across patient tissues and cancer cell-line models. HYPK expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HYPK is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, HYPK RNA expression shows 19,719 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where HYPK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HYPK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HYPK survival associations across molecular data types. HYPK RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HYPK RNA expression–survival associations across cancer types. High HYPK expression shows unfavorable associations in KIRC, UVM, ACC and PRAD, but favorable associations in BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HYPK RNA expression.
This table summarizes HYPK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HYPK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HYPK shows lower tumor expression in THCA and BRCA and higher tumor expression in LIHC, KIRC, BLCA and CHOL. The LIHC box plot shows higher HYPK RNA expression in tumor versus normal tissue (log2 FC = +0.275, t-test p < 0.001).
This table shows molecular features associated with HYPK in patient tissues and cancer cell lines. In patient samples, HYPK shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HYPK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
